Sun Pharmaceutical Industries Ltd News

Pharma stocks rally: Aurobindo, Divi's, Glenmark, Symbiotec hit new highs

Pharma stocks on a roll: Symbiotec Pharmalab, Windlas Biotech, Sai Life Sciences, Alembic Pharmaceuticals and Fermation Biotech were up in the range of 9-20% on Friday.

Sun Pharma Q2 net profit falls 36% on one-time charges, revenue rises 12%

Exceptional charges of Rs 1,268.8 crore, including a US antitrust settlement and Organon acquisition costs, weighed on profit, while India formulation sales grew 17.3 per cent

Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%

Among others, Mankind Pharma, Ipca Laboratories, Torrent Pharmaceuticals, Divis Laboratories, Cipla and Aurobindo Pharma were up 2% each in Friday's trade.

Sun Pharma's ILUMYA gets USFDA approval for psoriatic arthritis treatment

The US FDA approval expands ILUMYA's use beyond plaque psoriasis, adding a new treatment option for adults with active psoriatic arthritis

Stocks to watch: eMudhra, Infosys, Swiggy, HPCL, Havells, Sun Pharma, JSL

Stocks to watch today: eMudhra, Infosys, Swiggy, HPCL, Havells, Sun Pharma, Jindal Stainless, Rallis India, Infosys, JSW Steel, Tech Mahindra, among others, will be in focus today.

Stocks to watch: Eternal, Hindustan Zinc, YES Bank, Bajaj Fin, IREDA, LTTS

Stocks to watch: Eternal, Hindustan Zinc, YES Bank, Bajaj Finance, IREDA, LTTS, RailTel Corporation, Adani Green Energy, Indian Hotels Company, KEI Industries, among others, will be in action today.

Sun Pharma down 2%, stock hits over 5-month low

Thus far in the calendar year 2026, Sun Pharma outperformed the market and remained flat, as compared to a 14.7% decline in the BSE Sensex.

Expanding innovative portfolio may drive gains for Sun Pharma stock

Lerodalcibep licensing deal, growth in the US portfolio and tariff relief offer triggers, while the proposed Organon acquisition could broaden its global reach

India's Sun Pharma plans $1 billion local debt sale for loan takeout

MUMBAI, Sept 29 (Reuters) - India's Sun Pharmaceutical Industries is planning to raise around 100 ​billion rupees ($1.04 billion) via a upee-denominated debt sale ​to partly fund a bridge loan it took to acquire ‌US healthcare firm Organon & Co., three sources said on Tuesday.

Sun Pharma bags rights to $3.7 billion cholesterol drug market globally

Sun Pharma will commercialise and manufacture LIB Therapeutics' once-monthly cholesterol drug outside the US and China after its EU approval

On a healthy note! FPIs return to healthcare, pour ₹15,800 cr since July

In the first half of September, healthcare saw FPI inflows of ₹2,114 crore, the highest among all sectors, adding to the ₹5,931 crore and ₹7,755 crore buying seen in August and July, respectively.

NSE breaks into top 10 BSE market-cap league on debut; beats HUL, Titan

NSE's market capitalisation increased to ₹4.62 trillion to reach 10th position on the BSE, following a 5% rise in Thursday's debut trading session; beating HUL, Sun Pharma and Titan in ranking.

Pharma stocks zoom: Laurus Labs, Aurobindo hit new highs in trade

The BSE Healthcare index rallied over 1% in Monday's trade. Thus far in the financial year 2026-27, it outperformed the market by soaring 25%, against a near 4% rise in the BSE Sensex.

Stocks to watch: ICICI Pru AMC, Meesho, Wipro, Shakti Pumps, Hindustan Zinc

Stocks to watch: ICICI Pru AMC, Meesho, Wipro, Shakti Pumps, Hindustan Zinc, Sun Pharma, Bank of Baroda, Axis Bank, MCX, among others, will be in focus today.

Stocks to watch: Sun Pharma, Suzlon Energy, OMCs, Biocon, IHCL, Tata Power

Stocks to watch: Sun Pharma, Suzlon Energy, OMCs, Biocon, IHCL, Tata Power, TCS, Jio Financial Services, HCL Technologies, Emami Ltd, Bajaj Finance, among others, will be in focus today.

Sun Pharma gets ratings boost from Moody's, S&P over $11.75-bn Organon bid

Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries -- India's largest pharmaceutical company -- over the proposed USD 11.75-billion acquisition of US-based Organon & Co. S&P Global Ratings assigned a preliminary 'BBB+' long-term issuer credit rating, while Moody's Ratings assigned a 'Baa1' long-term issuer rating to the Indian pharmaceutical major. Both agencies have maintained a 'stable' outlook for the company. Baa1 and BBB+ are investment-grade credit ratings that indicate adequate payment capacity with moderate credit risk. The rating actions follow Sun Pharma's binding bid in April 2026 to acquire a 100 per cent stake in Organon for an enterprise value of USD 11.75 billion. The transaction is expected to close by March 2027, subject to regulatory approvals. According to S&P, the acquisition will bolster Sun Pharma's business position, almost doubling its revenue base to about Rs 1.3 trillion (around USD 14 billion) ..

Sun Pharma signs US deal to offer 'most favoured nation' pricing on drugs

Sun Pharmaceutical Industries on Tuesday announced it has entered into an agreement with the US government to prioritise access to affordable medicines for American patients. As part of the agreement, signed during a ceremony at the White House, Mumbai-based Sun Pharma, India's largest drugmaker, will extend 'Most Favoured Nation' (MFN) pricing to state Medicaid programmes, the company said in a regulatory filing on Tuesday. The commitment to MFN pricing will also apply to Sun Pharma's future innovative medicine launches in the US market, the filing said. MFN pricing generally ensures that a buyer receives the lowest price available for a drug. The agreement, which was signed alongside several other pharmaceutical companies, recognises Sun Pharma's investment in the US by delaying Section 232 tariffs on its innovative pharmaceutical products for over two years. The company did not disclose other terms of the deal. "The United States is a key area of investment and expansion for Su

F&O: Nifty sees healthy rollovers; eyes triangle breakout in Sep series

The Nifty August expiry delivered the most constructive positioning setup in four months, with improving rollover, rising carry and broader sectoral leadership, says Systematix in its F&O report.

Sun Pharma Q1 profit rises 27%; US generics remain under pressure

Sun Pharma reported a 27 per cent rise in Q1FY27 profit, driven by India and innovative medicines, while weakness in the US generics business continued to weigh on growth

Healthcare up for 4th straight month; Divis, Laurus, Torrent at new highs

The BSE Healthcare hit a new high of 51,108 on Friday, rallying 3.7% in July. The index has surged 22% since April 2026.